Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aura Clear all
Not listed Phase 2Phase 3 Interventional

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

NCT00283738
View directory record Official record
Conditions
Migraine, Aura, Patent Foramen Ovale
Interventions
BioSTAR Septal Repair Implant System, Sham Procedure
Device · Procedure
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Stamford, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

NCT02614287
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

NCT02560025
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Alisertib, Cytarabine, Idarubicin, Daunorubicin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

NCT03338920
View directory record Official record
Conditions
Acute Migraine With or Without Aura
Interventions
sumatriptan nasal powder, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated No phase listed Observational

TAURAS - T790 AURA ScreenFailure SOC Registry Study

NCT02405247
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Patient Reported Outcome (PRO)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Oceanside, California • Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Jul 21, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

A Comprehensive Digital Care Program for Migraine Management

NCT07642414
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Neuromodulation Wearable Device, Migraine Digital Care Program
Device · Other
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine

NCT01828684
View directory record Official record
Conditions
Migraine Disorders, Photophobia
Interventions
Therapeutic Lens Coating, Sham Lens Coating
Other
Lead sponsor
Bradley Katz
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jul 21, 2026, 5:31 PM EDT
Not listed Phase 1Phase 2 Interventional

Treatment of Chronic Migraine Headaches.

NCT03220113
View directory record Official record
Conditions
Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions
Dexamethasone, Lidocaine, Thiamine cohort
Combination Product
Lead sponsor
Corona Doctors Medical Clinics, Inc.
Other
Eligibility
10 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Corona, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03237845
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

EmbracePlus, Care App and Aura Usability Study

NCT04807608
View directory record Official record
Conditions
Usability
Interventions
Usability Assessment
Other
Lead sponsor
Empatica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

NCT01316692
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
Interventions
laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays, TdT-mediated dUTP nick end labeling assay, mass spectrometry
Other · Procedure · Genetic
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Cooling to Alleviate Migraine #3

NCT06874361
View directory record Official record
Conditions
Migraine With or Without Aura, Migraine, Migraine Headache
Interventions
Mi-Helper
Device
Lead sponsor
Mi-Helper, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Indian Harbour Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebos
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
117
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

NCT01567709
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Alisertib, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT04100135
View directory record Official record
Conditions
Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
Interventions
Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Barbara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Not yet recruiting Phase 2 Interventional

Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

NCT07706179
View directory record Official record
Conditions
HR+/HER2+ Breast Cancer, Metastatic Breast Cancer
Interventions
Alisertib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

NCT00792636
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

NCT00297102
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Fullerton, California • Los Angeles, California • Palmdale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study of NXN 188 for the Treatment of Migraine With Aura

NCT00920686
View directory record Official record
Conditions
Migraine With Aura
Interventions
NXN-188, placebo, sumatriptan succinate
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Newport Beach, California • Oceanside, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Results available

Transnasal Cooling for Migraine

NCT04936061
View directory record Official record
Conditions
Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
Interventions
CoolStat active device, CoolStat sham device
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • East Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

NCT01397825
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
Interventions
Alisertib (MLN8237), Rituximab, Vincristine
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Burbank, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Open Label Safety Study in Acute Treatment of Migraine

NCT03266588
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
98
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Adult Subjects With Acute Migraines

NCT03235479
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Integrative Migraine Pain Alleviation Through Chiropractic Therapy

NCT03177616
View directory record Official record
Conditions
Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Migraine, Classic
Interventions
Chiropractic Treatment
Other
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 21, 2026, 5:31 PM EDT